Tylent brings Lyvra IV compounding platform to France

Tylent Technologies will unveil Lyvra™, an AI- and maglev-powered platform for hospital IV compounding, at the GERPAC/ESHPT congress Sept. 30-Oct. 2 in Hyères, France. The launch targets European hospitals and compounding centers that need higher throughput, more automation and better workflow integration.

Why it matters: - Lyvra™ is aimed at one of hospital pharmacy’s hardest bottlenecks: sterile IV compounding. - Tylent says the platform is built to raise throughput and scalability in European pharmacies and compounding units. - The launch comes as IV compounding automation remains below 1% adoption in Europe. - The platform is positioned for oncology and monoclonal antibody workflows, where demand and complexity are high.

What happened: - Tylent Technologies will debut Lyvra™ at the GERPAC/ESHPT congress in Hyères, France, on Sept. 30, Oct. 1 and Oct. 2, 2026. - The company is presenting the platform to French hospital pharmacists in French and English. - Attendees will be able to see Lyvra™ running at the event. - Gaspar G. de Viedma will also lead private technology meetings during the congress.

The details: - Lyvra™ is described as a new European-designed platform for automating IV bag preparation. - The system combines AI-driven workflow orchestration with maglev technology developed by Beckhoff Automation. - Tylent says the architecture enables true parallel processing and multitasking rather than serial, single-task robotics. - The platform is designed to support end-to-end workflow integration from stock to patient. - Lyvra™ is built for hospital cleanrooms and centralized IV compounding units, including CIVAS. - The platform is intended to support ISO 5 controlled cleanroom environments. - Tylent says the system automates preparation of ready-to-administer IV doses. - The company says the design reduces dependence on scarce pharmacy and nursing labor. - Tylent Technologies is a brand of Groupe GPI.

Between the lines: - The launch frames Lyvra™ as a break from older automation systems that copied manual steps instead of redesigning the full workflow. - Tylent argues that serial, robotized processes have limited speed, scalability and integration in European pharmacy operations. - The timing reflects broader pressure on health systems from aging populations, drug shortages and staffing gaps. - The company is also signaling a push into markets that want more traceability and production capacity without expanding headcount.

What's next: - Tylent expects private, invitation-only meetings to showcase Lyvra™’s architecture and capabilities in more detail. - Interested attendees can request access by contacting arturo.caissut@tylent-technologies.com. - Press inquiries should also go to arturo.caissut@tylent-technologies.com. - More information is available in the company announcement.